{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:12:01Z","timestamp":1794276721038,"version":"4.9.0"},"reference-count":106,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>It is crucial to consider newer antibiotics with activity against anaerobes and Helicobacter pylori, given their healthcare importance, and the constantly growing antibiotic resistance\/multidrug resistance, which complicates the therapy. The aim of this review was to emphasize certain recently approved or still-under-investigation antibiotics with potential benefits for treating Clostridioides difficile infections (CDIs), other anaerobic infections, and those caused by H. pylori, covering recent data from articles published primarily in 2020\u20132026. Given the limited number of antibiotics for treating CDI and fidaxomicin nonavailability in many countries, it is necessary to conduct more extensive laboratory and clinical studies of promising antibiotics such as ibezapolstat, delafloxacin, lascufloxacin, omadacycline, eravacycline, ridinilazole, and CRS3123. Against Bacteroides fragilis group species, delafloxacin and eravacycline showed good activity. Research on rifasutenizol for bacterial vaginosis, sarecycline and nadifloxacin for acne vulgaris and amixicile for periodontal diseases needs to be expanded. For H. pylori infection, delafloxacin, sitafloxacin, nemonoxacin, zoliflodacin, and rifasutenizol may improve the suboptimal success of most eradication regimens. However, more efforts, in coordination between medical, scientific, manufacturing, and government representatives, should ensure wider access to and research on the newer antibacterials. Establishing more research groups, careful examination of market issues, and additional approaches, such as nanomaterials, efflux pump inhibitors, phage therapy, and CRISPR-Cas systems, should be beneficial. Notwithstanding the difficulties, there are many opportunities to promote research on and potential use of newer antibiotics which show advantages over the older antibacterials, and to make them available to numerous countries and patients worldwide.<\/jats:p>","DOI":"10.3390\/antibiotics15060581","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:43:46Z","timestamp":1780897426000},"page":"581","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Some Newer Antibiotics Active Against Helicobacter pylori and Anaerobic Bacteria and the Potential Benefits of Their Wider Availability in More Countries: A Narrative Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9622-0873","authenticated-orcid":false,"given":"Lyudmila","family":"Boyanova","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology, Medical University of Sofia, 2 Zdrave St, 1431 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-2741","authenticated-orcid":false,"given":"Liliya Yordanova","family":"Boyanova","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Medical University of Sofia, 2 Zdrave St, 1431 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8669-5550","authenticated-orcid":false,"given":"Jos\u00e9","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Coimbra, 3000 Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1028-4245","authenticated-orcid":false,"given":"Georgi","family":"Dimitrov","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Medical University of Sofia, 2 Zdrave St, 1431 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5370-7542","authenticated-orcid":false,"given":"Petyo","family":"Hadzhiyski","sequence":"additional","affiliation":[{"name":"Children\u2019s Gastroenterology Clinic, Specialized Hospital for Active Pediatric Treatment \u201cProf. Dr. Ivan Mitev\u201d, Medical University-Sofia, 1431 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3605-6447","authenticated-orcid":false,"given":"Raina","family":"Gergova","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Medical University of Sofia, 2 Zdrave St, 1431 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1634-8768","authenticated-orcid":false,"given":"Rumyana","family":"Markovska","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Medical University of Sofia, 2 Zdrave St, 1431 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"102559","DOI":"10.1016\/j.anaerobe.2022.102559","article-title":"Antimicrobial susceptibility testing of anaerobic bacteria: In routine and research","volume":"75","author":"Sood","year":"2022","journal-title":"Anaerobe"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"102606","DOI":"10.1016\/j.anaerobe.2022.102606","article-title":"Carbapenem resistance in Bacteroides fragilis: A review of molecular mechanisms","volume":"76","author":"Yekani","year":"2022","journal-title":"Anaerobe"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"102173","DOI":"10.1016\/j.anaerobe.2020.102173","article-title":"Surveillance of antimicrobial resistance in recent clinical isolates of Gram-negative anaerobic bacteria in a Greek University Hospital","volume":"62","author":"Maraki","year":"2020","journal-title":"Anaerobe"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e1429","DOI":"10.1002\/mbo3.1429","article-title":"New functions of pirin proteins and a 2-ketoglutarate: Ferredoxin oxidoreductase ortholog in Bacteroides fragilis metabolism and their impact on antimicrobial susceptibility to metronidazole and amixicile","volume":"13","author":"Gough","year":"2024","journal-title":"Microbiologyopen"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e0013523","DOI":"10.1128\/cmr.00135-23","article-title":"Clostridioides difficile infection: History, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options","volume":"37","author":"Sanson","year":"2024","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Markovska, R., Dimitrov, G., Niyazi, D., Stoeva, T., Mihova, K., and Boyanova, L. (2026). Molecular epidemiology of toxigenic Clostridioides difficile isolated from Bulgarian patients and the prevalence of hypervirulent ST1 clone. Microorganisms, 14.","DOI":"10.3390\/microorganisms14030532"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bcp.2016.09.025","article-title":"Antibiotics in late clinical development","volume":"133","author":"Fernandes","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.gtc.2021.02.010","article-title":"A Review of Clostridioides difficile Infection and antibiotic-associated diarrhea","volume":"50","author":"Abad","year":"2021","journal-title":"Gastroenterol. Clin. North Am."},{"key":"ref_9","first-page":"180","article-title":"Approved antibacterial drugs in the last 10 years: From the bench to the clinic","volume":"1","author":"Sarabia","year":"2023","journal-title":"Explor. Drug Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101151","DOI":"10.1016\/j.lanepe.2024.101151","article-title":"Comparative effectiveness of different therapies for Clostridioides difficile infection in adults: A systematic review and network meta-analysis of randomized controlled trials","volume":"49","author":"Simon","year":"2025","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Dasc\u0103lu, R.I., Bolocan, A., P\u0103duaru, D.N., Constantinescu, A., Mitache, M.M., Stoica, A.D., and Andronic, O. (2023). Multidrug resistance in Helicobacter pylori infection. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1128497"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"327745","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: The Maastricht VI\/Florence consensus report","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"117012","DOI":"10.1016\/j.diagmicrobio.2025.117012","article-title":"Delafloxacin and levofloxacin activities on Helicobacter pylori in Bulgaria over four years","volume":"113","author":"Boyanova","year":"2025","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41575-021-00449-x","article-title":"Helicobacter pylori infection and antibiotic resistance\u2014From biology to clinical implications","volume":"18","author":"Yamaoka","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.3346\/jkms.2024.39.e44","article-title":"Resistance of Helicobacter pylori: Mechanisms and clinical implications","volume":"39","author":"Hasanuzzaman","year":"2024","journal-title":"J. Korean Med. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Sora, V.M., Wallet, C., Meroni, G., Loustau, T., Rohr, O., Zecconi, A., and Schwartz, C. (2026). Antimicrobial Resistance: How can we overcome the problem?. Antibiotics, 15.","DOI":"10.3390\/antibiotics15010082"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1021\/acsinfecdis.4c00128","article-title":"Gyrase and topoisomerase IV: Recycling old targets for new antibacterials to combat fluoroquinolone resistance","volume":"10","author":"Collins","year":"2024","journal-title":"ACS Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Rusu, A., Lungu, I.A., Moldovan, O.L., Tanase, C., and Hancu, G. (2021). Structural characterization of the millennial antibacterial (fluoro)quinolones-shaping the fifth generation. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13081289"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kocsis, B., Guly\u00e1s, D., and Szab\u00f3, D. (2021). Delafloxacin, finafloxacin, and zabofloxacin: Novel fluoroquinolones in the antibiotic pipeline. Antibiotics, 10.","DOI":"10.3390\/antibiotics10121506"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1871525717666190402121958","article-title":"Fluoroquinolones and the risk of aortic aneurysm or aortic dissection: A systematic review and meta-analysis","volume":"17","author":"Rawla","year":"2019","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Turban, A., Gu\u00e9rin, F., Dinh, A., and Cattoir, V. (2023). Updated review on clinically-relevant properties of delafloxacin. Antibiotics, 12.","DOI":"10.3390\/antibiotics12081241"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1038\/s41467-025-60688-3","article-title":"Structural basis of topoisomerase targeting by delafloxacin","volume":"16","author":"Najmudin","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"ofz514","DOI":"10.1093\/ofid\/ofz514","article-title":"A Phase 3 Study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP)","volume":"7","author":"Horcajada","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102150","DOI":"10.1016\/j.anaerobe.2020.102150","article-title":"Activity of delafloxacin versus that of levofloxacin against anaerobic and microaerophilic isolates","volume":"62","author":"Boyanova","year":"2020","journal-title":"Anaerobe"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1093\/jac\/dkae269","article-title":"In vitro activity of delafloxacin against clinical levofloxacin-resistant Helicobacter pylori isolates","volume":"79","author":"Luzarraga","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/1062936X.2023.2230876","article-title":"Predictive profiling of gram-negative antibiotics in CagA oncoprotein inactivation: A molecular dynamics simulation approach","volume":"34","author":"Varshney","year":"2023","journal-title":"SAR QSAR Environ. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"102346","DOI":"10.1016\/j.anaerobe.2021.102346","article-title":"In vivo pharmacodynamics of lascufloxacin and levofloxacin against Streptococcus pneumoniae and Prevotella intermedia in a pneumonia mixed-infection mouse model","volume":"69","author":"Hagihara","year":"2021","journal-title":"Anaerobe"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.anaerobe.2018.08.002","article-title":"In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group","volume":"54","author":"Yamagishi","year":"2018","journal-title":"Anaerobe"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"102483","DOI":"10.1016\/j.jiac.2024.07.023","article-title":"Temporal effects of lascufloxacin on human gut and salivary microbiota: Analysis using next-generation sequencing method","volume":"31","author":"Mukuda","year":"2025","journal-title":"J. Infect. Chemother."},{"key":"ref_30","first-page":"e37650","article-title":"Safety and Efficacy of nemonoxacin vs levofloxacin in patients with community-acquired pneumonia: A systematic review and meta-analysis of randomized control trials","volume":"15","author":"Khan","year":"2023","journal-title":"Cureus"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Yin, H., Shao, Y., and Sun, F. (2025). The latest research progress on the clinical application of nemonoxacin. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1671640"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Lee, C.C., Yan, X.Z., Wu, H.T., Ko, W.C., Tsai, P.J., and Hung, Y.P. (2024). Potential effectiveness of parenteral nemonoxacin in the treatment of Clostridioides difficile infections: In vitro, ex vivo, and mouse studies. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1418817"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Kuhn, E.M.A., Sominsky, L.A., Chitt\u00f2, M., Schwarz, E.M., and Moriarty, T.F. (2024). Antibacterial mechanisms and clinical impact of sitafloxacin. Pharmaceuticals, 17.","DOI":"10.3390\/ph17111537"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Choi, Y.I., Lee, S.M., Chung, J.W., Kim, K.O., Kwon, K.A., Kim, Y.J., Kim, J.H., Lee, S.M., Jeong, J.Y., and Park, D.K. (2021). Therapeutic potential of sitafloxacin as a new drug candidate for Helicobacter eradication in Korea: An in vitro culture-based study. Antibiotics, 10.","DOI":"10.3390\/antibiotics10101242"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.anl.2020.12.005","article-title":"Odontogenic infection and antiresorptive agent-related osteonecrosis of the jaw with facial subcutaneous abscess formation: A retrospective clinical study of difficult-to-diagnose cases","volume":"48","author":"Matsumoto","year":"2021","journal-title":"Auris Nasus Larynx"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Nishizawa, T., Munkjargal, M., Ebinuma, H., Toyoshima, O., and Suzuki, H. (2021). Sitafloxacin for third-line Helicobacter pylori eradication: A systematic review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10122722"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1159\/000546914","article-title":"Efficacy of vonoprazan-based triple therapy with sitafloxacin and amoxicillin for third-line Helicobacter pylori eradication: A multicenter prospective analysis on drug resistance and gyrA mutations","volume":"43","author":"Wasaki","year":"2025","journal-title":"Dig. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Dauyey, K., Zhunussova, G., Kaibullayeva, J., Bondar, Y., Yerzhan, A., Medetbekova, A., Kaisina, A., Khabizhanova, A., Seitbekov, K., and Yamaoka, Y. (2026). A single-center culture-based study of Helicobacter pylori in Kazakhstan with regional meta-analysis of prevalence and antibiotic resistance. Front. Microbiol., 17.","DOI":"10.3389\/fmicb.2026.1747006"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Mori, H., Saito, Y., Ando, H., Masaoka, T., Matsuzaki, J., Nakano, M., and Kanai, T. (2026). Third-line and later susceptibility-guided Helicobacter pylori eradication therapies: A multicenter study of vonoprazan-amoxicillin-sitafloxacin\/rifabutin regimens. J. Clin. Med., 15.","DOI":"10.3390\/jcm15020434"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Geeratragool, T., Tansirichaiya, S., Kamolvit, W., Atthakitmongkol, T., Leartsiwawinyu, W., Thaipisuttikul, I., Chuenprapai, P., Leelakusolvong, S., Limwong, C., and Maneerattanaporn, M. (2025). Efficacy of a 7-day vonoprazan, sitafloxacin, and amoxicillin triple therapy as a fourth-line salvage regimen for refractory Helicobacter pylori infection. BMC Gastroenterol., 25.","DOI":"10.1186\/s12876-025-04226-x"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"El Boury, K., Boudarf, H., Adoud, I., Ouannass, S., Abi, O., Delsa, H., Lahlou, F.A., Iskandar, S., El Jemli, M., and Diawara, I. (2025). Clinical effectiveness of penicillin-free therapies in first-line and rescue treatments for Helicobacter pylori: A systematic review. Antibiotics, 14.","DOI":"10.3390\/antibiotics14050476"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.31557\/APJCP.2025.26.9.3127","article-title":"Characteristics of successful third-line eradication of Helicobacter pylori based on antibiotic susceptibility","volume":"26","author":"Suzuki","year":"2025","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Dur\u00e3es, F., and Sousa, E. (2019). A newly approved antibacterial from the class of tetracyclines. Pharmaceuticals, 12.","DOI":"10.3390\/ph12020063"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1080\/07853890.2022.2085881","article-title":"Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance","volume":"54","author":"LaPlante","year":"2022","journal-title":"Ann. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40265-019-01067-3","article-title":"Eravacycline: A review in complicated intra-abdominal infections","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Falagas, M.E., Romanos, L.T., Kontogiannis, D.S., Filippou, C., and Karageorgopoulos, D.E. (2025). Resistance of gram-negative bacteria to eravacycline: A systematic review of data from in vitro studies. Pathogens, 14.","DOI":"10.3390\/pathogens14121214"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s42003-020-0966-5","article-title":"Tetracycline-inactivating enzymes from environmental, human commensal, and pathogenic bacteria cause broad-spectrum tetracycline resistance","volume":"3","author":"Gasparrini","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e0235123","DOI":"10.1128\/spectrum.02351-23","article-title":"Eravacycline, the first four years: Health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022","volume":"12","author":"Alosaimy","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clinmicnews.2023.04.001","article-title":"Review of novel third-generation tetracyclines: Eravacycline, omadacycline, and sarecycline","volume":"45","author":"Kim","year":"2023","journal-title":"Clin. Microbiol. Newsl."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"117306","DOI":"10.1016\/j.diagmicrobio.2026.117306","article-title":"In vitro activity of eravacycline compared to other antibiotics commonly used for treatment of infections involving anaerobic bacteria: A review of the literature and our own data","volume":"115","author":"Boyanova","year":"2026","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.anaerobe.2018.06.016","article-title":"In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species","volume":"52","author":"Goldstein","year":"2018","journal-title":"Anaerobe"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e02206","DOI":"10.1128\/AAC.02206-17","article-title":"Evaluation of the in vitro activity of eravacycline against a broad spectrum of recent clinical anaerobic isolates","volume":"62","author":"Snydman","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgar.2024.03.014","article-title":"Antimicrobial activity of eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in Taiwan: A clinical microbiological study","volume":"37","author":"Tsai","year":"2024","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Wolf, L.J., and Stingu, C.S. (2023). Antimicrobial susceptibility profile of rare anaerobic bacteria. Antibiotics, 12.","DOI":"10.3390\/antibiotics12010063"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/jac\/dkaa289","article-title":"In vitro activity of eravacycline against common ribotypes of Clostridioides difficile","volume":"75","author":"Begum","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/dkaa386","article-title":"Eravacycline, a novel tetracycline derivative, does not induce Clostridioides difficile infection in an in vitro human gut model","volume":"76","author":"Buckley","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"115129","DOI":"10.1016\/j.diagmicrobio.2020.115129","article-title":"In vitro activity of new tetracycline analogues omadacycline and eravacycline against clinical isolates of Helicobacter pylori collected in China","volume":"98","author":"Yang","year":"2020","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2147\/CCID.S190473","article-title":"Sarecycline: A review of preclinical and clinical evidence","volume":"13","author":"Moore","year":"2020","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1093\/nar\/gkad103","article-title":"Sarecycline inhibits protein translation in Cutibacterium acnes 70S ribosome using a two-site mechanism","volume":"51","author":"Lomakin","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jaad.2023.12.038","article-title":"Epidemiology of acne and rosacea: A worldwide global study","volume":"90","author":"Saurat","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e13386","DOI":"10.1111\/srt.13386","article-title":"Prevalence and risk factors of acne scars in patients with acne vulgaris","volume":"29","author":"Liu","year":"2023","journal-title":"Skin Res. Technol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/ASW.0000000000000089","article-title":"Clinical aspects and treatments","volume":"37","author":"Geng","year":"2024","journal-title":"Adv. Ski. Wound Care"},{"key":"ref_63","first-page":"5","article-title":"Sarecycline: A Narrow-Spectrum Antibiotic","volume":"27","author":"Adjei","year":"2022","journal-title":"Ski. Ther. Lett."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Di Stefano, M., Polizzi, A., Santonocito, S., Romano, A., Lombardi, T., and Isola, G. (2022). Impact of oral microbiome in periodontal health and periodontitis: A Critical review on prevention and treatment. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23095142"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12010-022-04127-9","article-title":"Periodontitis: An oral disease with severe consequences","volume":"195","author":"Ray","year":"2023","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"acmi000177","DOI":"10.1099\/acmi.0.000177","article-title":"Prevalence of target anaerobes associated with chronic periodontitis","volume":"2","author":"Alazemi","year":"2020","journal-title":"Access Microbiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"10474","DOI":"10.1038\/s41598-017-09616-0","article-title":"Amixicile, a novel strategy for targeting oral anaerobic pathogens","volume":"7","author":"Hutcherson","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_68","first-page":"CD012568","article-title":"Adjunctive systemic antimicrobials for the non-surgical treatment of periodontitis","volume":"11","author":"Khattri","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.job.2020.03.004","article-title":"Amixicile depletes the ex vivo periodontal microbiome of anaerobic bacteria","volume":"62","author":"Gui","year":"2020","journal-title":"J. Oral Biosci."},{"key":"ref_70","first-page":"138","article-title":"Amixicile: A concept therapeutic for treatment of chronic anaerobic infections","volume":"2","author":"Hoffman","year":"2020","journal-title":"Br. J. Gastroenterol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1128\/AAC.03112-14","article-title":"Preclinical studies of amixicile, a systemic therapeutic developed for treatment of Clostridium difficile infections that also shows efficacy against Helicobacter pylori","volume":"58","author":"Hoffman","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Sargianou, M., Stathopoulos, P., Vrysis, C., Tzvetanova, I.D., and Falagas, M.E. (2025). New \u03b2-lactam\/\u03b2-lactamase inhibitor combination antibiotics. Pathogens, 14.","DOI":"10.3390\/pathogens14040307"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e0190821","DOI":"10.1128\/Spectrum.01908-21","article-title":"Activity of aztreonam-avibactam against 341 recent clinical isolates of anaerobes","volume":"9","author":"Snydman","year":"2021","journal-title":"Microbiol. Spectr."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/17425255.2024.2427310","article-title":"Cefepime\/enmetazobactam: A microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation","volume":"21","author":"Darlow","year":"2025","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2217\/fmb-2018-0054","article-title":"Meropenem-vaborbactam: A new weapon in the war against infections due to resistant Gram-negative bacteria","volume":"13","author":"Patel","year":"2018","journal-title":"Future Microbiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.2147\/IDR.S224228","article-title":"A clinical review and critical evaluation of imipenem-relebactam: Evidence to date","volume":"13","author":"Campanella","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"107198","DOI":"10.1016\/j.ijantimicag.2024.107198","article-title":"Fighting against Clostridioides difficile infection: Current medications","volume":"64","author":"Quan","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"9465","DOI":"10.1021\/acs.jmedchem.4c00558","article-title":"Discovery and structure-activity relationship of cadazolid: A first-in-class quinoxolidinone antibiotic for the treatment of Clostridioides difficile Infection","volume":"67","author":"Rueedi","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_79","first-page":"134","article-title":"Novel drug candidates against antibiotic-resistant microorganisms: A review","volume":"27","author":"Lim","year":"2024","journal-title":"Iran. J. Basic Med. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1473-3099(25)00721-2","article-title":"Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: A phase 2, randomised, double-blind, multicentre, vancomycin-controlled study","volume":"26","author":"Louie","year":"2026","journal-title":"Lancet Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e02165-21","DOI":"10.1128\/aac.02165-21","article-title":"In vitro activity of gepotidacin against Gram-negative and Gram-positive anaerobes","volume":"66","author":"Hackel","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(25)00628-2","article-title":"Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): A phase 3 randomised, open-label, non-inferiority, multicentre study","volume":"405","author":"Ross","year":"2025","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"101126","DOI":"10.1016\/j.lanmic.2025.101126","article-title":"Ibezapolstat Phase 2 Investigator Group. Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with Clostridioides difficile infection: A phase 2b, randomised, double-blind, active-controlled, multicentre study","volume":"6","author":"Eubank","year":"2025","journal-title":"Lancet Microbe"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/joim.13378","article-title":"Clinical use of lefamulin: A first-in-class semisynthetic pleuromutilin antibiotic","volume":"291","author":"Covvey","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"115413","DOI":"10.1016\/j.ejmech.2023.115413","article-title":"Antibiotics with novel mode of action as new weapons to fight antimicrobial resistance","volume":"256","author":"Ruggieri","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1093\/cid\/ciaa336","article-title":"A Novel semisynthetic pleuromutilin antibiotic for community-acquired bacterial pneumonia","volume":"71","author":"Watkins","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/ciad792","article-title":"A randomized, double-blind, phase 3 safety and efficacy study of ridinilazole versus vancomycin for treatment of Clostridioides difficile Infection: Clinical outcomes with microbiome and metabolome correlates of response","volume":"78","author":"Okhuysen","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40265-022-01832-x","article-title":"Emerging options for the prevention and management of Clostridioides difficile infection","volume":"83","author":"Carlson","year":"2023","journal-title":"Drugs"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"G227","DOI":"10.1152\/ajpgi.00046.2020","article-title":"Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids","volume":"319","author":"Qian","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1093\/cid\/ciaf188","article-title":"Subgroup analyses in randomized trials of Clostridioides difficile-associated disease: Recurring challenges with analyzing recurrence","volume":"81","author":"Strength","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1080\/17460441.2025.2552145","article-title":"The state of the art in dual-acting hybrid antibiotics to combat bacterial resistance","volume":"20","author":"Parkes","year":"2025","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1021\/acs.jmedchem.1c02045","article-title":"Design, synthesis, and characterization of TNP-2198, a dual-targeted rifamycin-nitroimidazole conjugate with potent activity against microaerophilic and anaerobic bacterial pathogens","volume":"65","author":"Ma","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S1473-3099(24)00003-3","article-title":"Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: Four randomised clinical trials","volume":"24","author":"Li","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1473-3099(25)00438-4","article-title":"Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): A phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial","volume":"26","author":"Song","year":"2026","journal-title":"Lancet Infect. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00284-024-03761-2","article-title":"Efficacy of zoliflodacin, a spiropyrimidinetrione antibiotic, against gram-negative pathogens","volume":"81","author":"Oyardi","year":"2024","journal-title":"Curr. Microbiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e13075","DOI":"10.1111\/hel.13075","article-title":"Evaluating the potency of zoliflodacin against Helicobacter pylori: In vitro activity and conserved GyrB target","volume":"29","author":"Liu","year":"2024","journal-title":"Helicobacter"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Shi, Z., Zhang, J., Tian, L., Xin, L., Liang, C., Ren, X., and Li, M. (2023). A Comprehensive overview of the antibiotics approved in the last two decades: Retrospects and prospects. Molecules, 28, Erratum in Molecules\u00a02025, 30, 209. https:\/\/doi.org\/10.3390\/molecules30020209.","DOI":"10.3390\/molecules30020209"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2147\/IDR.S357473","article-title":"Helicobacter pylori biofilm-related drug resistance and new developments in its anti-biofilm agents","volume":"15","author":"Hou","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/cid\/cix833","article-title":"Low risk of primary Clostridium difficile infection with tetracyclines: A systematic review and metaanalysis","volume":"66","author":"Tariq","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e0112922","DOI":"10.1128\/aac.01129-22","article-title":"Antibiotic-specific risk for community-acquired Clostridioides difficile infection in the United States from 2008 to 2020","volume":"66","author":"Zhang","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Rusu, A., Munteanu, A.C., Arb\u0103na\u0219i, E.M., and Uivarosi, V. (2023). Overview of side-effects of antibacterial fluoroquinolones: New drugs versus old drugs, a step forward in the safety profile?. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030804"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e000227","DOI":"10.1136\/bmjmed-2022-000227","article-title":"Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: Cohort study of FDA approved drugs","volume":"1","author":"Powers","year":"2022","journal-title":"BMJ Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S2214-109X(21)00463-0","article-title":"Global access to existing and future antimicrobials and diagnostics: Antimicrobial subscription and pooled procurement","volume":"10","author":"Berman","year":"2022","journal-title":"Lancet Glob. Health"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"100705","DOI":"10.1016\/j.lanepe.2023.100705","article-title":"Challenges and opportunities for incentivising antibiotic research and development in Europe","volume":"33","author":"Anderson","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Parvin, N., Joo, S.W., and Mandal, T.K. (2025). Nanomaterial-based strategies to combat antibiotic resistance: Mechanisms and applications. Antibiotics, 14.","DOI":"10.3390\/antibiotics14020207"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s00284-022-03029-7","article-title":"Emerging non-traditional approaches to combat antibiotic resistance","volume":"79","author":"Konwar","year":"2022","journal-title":"Curr. Microbiol."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/6\/581\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T06:26:39Z","timestamp":1780899999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/6\/581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,7]]},"references-count":106,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["antibiotics15060581"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15060581","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,7]]}}}